Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5 USD | 0.00% | +5.49% | +64.01% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 84.86M 6.79B |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.84B | Net income 2025 * | -27M -2.16B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.38
x | P/E ratio 2025 * |
-2.76
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.9% |
Latest transcript on Aileron Therapeutics, Inc.
1 week | +5.49% | ||
Current month | -24.59% | ||
1 month | -27.86% | ||
3 months | -0.79% | ||
6 months | +323.73% | ||
Current year | +64.01% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 30/10/23 |
Director of Finance/CFO | 48 | 30/09/23 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/10/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 18/06/19 | |
Alan Musso
BRD | Director/Board Member | 61 | 30/10/23 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 30/10/23 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 5 | 0.00% | 85,369 |
25/04/24 | 5 | +1.42% | 80,550 |
24/04/24 | 4.93 | +3.79% | 102,254 |
23/04/24 | 4.75 | 0.00% | 67,716 |
22/04/24 | 4.75 | +0.21% | 109,866 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.01% | 84.86M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALRN Stock